Vous avez cherché: consider (Néerlandais - Danois)

points to consider on the evaluation of
sendt til høring i oktober 2000

products points to consider on the reduction,
revision of section 3. 2. 5 of cpmp note for guidance on plasma- derived medicinal products

points to consider on adjustment for baseline covariates
points to consider on adjustment for baseline covariates

points to consider on the evaluation of diagnostic agents
points to consider on the evaluation of diagnostic agents

points to consider on multiplicity issues in clinical trials
points to consider on missing data points to consider on multiplicity issues in clinical trials

points to consider on multiplicity issues in clinical trials.
points to consider on multiplicity issues in clinical trials.

points to consider on xenogeneic cell therapy for medicinal products
points to consider on xenogeneic cell therapy for medicinal products

points to consider on the assessment of anti- hiv medicinal products
points to consider on the assessment of anti- hiv medicinal products

points to consider on xenogeneic cell therapy note for guidance on the production and
concept paper on the development of a points to consider on xenogeneic cell therapy

of medicinal products in the treatment of acute stroke points to consider on validity and
points to consider on clinical investigation of medicinal products in the treatment of acute stroke

investigation of medicinal products in pain management points to consider on pharmaco-kinetics
concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in pain management

investigation of medicinal products in the treatment of diabetes mellitus points to consider on clinical investigation
concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus

and pharmacodynamics in the development of anti-bacterial medicinal products points to consider on switching between
points to consider on pharmaco- kinetics and pharmacodynamics in the development of anti- bacterial medicinal products

points to consider on application with 1) meta- analyses and 2) one pivotal study
points to consider on application with 1) meta - analyses and 2) one pivotal study

points to consider on quality aspects of medicinal products containing active substances produced by stable transgene experession in higher plants
points to consider on quality aspects of medicinal products containing active substances produced by stable transgene experession in higher plants

concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.
concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.

concept paper on the development of a cpmp points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections
concept paper on the development of a cpmp points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections

investigation of medicinal products in the treatment of asthma concept paper on the development of a cpmp points to consider on biostatistical/methodological issues arising
concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in the treatment of asthma

furthermore, they state that they consider the aid to have been compatible with guidelines for the examination of state aid to fisheries and aquaculture applicable at the times concerned.
furthermore, they state that they consider the aid to have been compatible with guidelines for the examination of state aid to fisheries and aquaculture applicable at the times concerned.

choice of non-inferiority margin points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
choice of non- inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: